Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help? - PubMed (original) (raw)
Review
doi: 10.1038/bmt.2012.76. Epub 2012 May 14.
Affiliations
- PMID: 22580766
- DOI: 10.1038/bmt.2012.76
Review
Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?
Y P L Linhares et al. Bone Marrow Transplant. 2013 Feb.
Abstract
Chronic GVHD (cGVHD) is an important problem after allotransplants. Some risk factors for cGVHD are similar to those of acute GVHD (aGVHD) but others are distinct indicating sometimes overlapping but unique pathogeneses. Precise incidence and prevalence data of cGVHD are lacking because of diverse diagnostic criteria but a 50% risk is a reasonable estimate. Incidence and prevalence of cGVHD are probably growing because of increased use of unrelated donors, blood rather than bone marrow (BM) grafts, decreased early transplant-related mortality (TRM) and increasing frequency of allotransplants. Pathophysiology of cGVHD is complex and poorly understood. Notably, no reliable surrogate end point to predict mechanism(s) of cGVHD has been identified. Therapy of cGVHD is unsatisfactory. Corticosteroids are effective but other drugs are controversial and few are rigorously tested in randomized trials. Highly variable response rates are reported because of small sample sizes and inconsistencies in eligibility, diagnostic and response criteria. We focus on the possible role of immunomodulatory drugs (IMiDs), thalidomide lenalidomide and pomalidomide, in preventing and treating cGVHD. The data suggest activity of thalidomide but at doses not clinically practical in many instances. There are few data with lenalidomide. Trials of pomalidomide, which has immune activities like thalidomide but with fewer adverse effects, are beginning. Because cGVHD is not recently reviewed in Bone Marrow Transplantation, we give a brief background and discuss challenges in diagnosing, understanding and treating cGVHD including the recently proposed National Institutes of Health consensus criteria for cGVHD.
Similar articles
- Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, Engelhardt B, Goodman S, Greer J, Kassim A, Morgan D, Ruffner K, Schuening F. Jagasia M, et al. Biol Blood Marrow Transplant. 2007 Oct;13(10):1207-15. doi: 10.1016/j.bbmt.2007.07.001. Epub 2007 Aug 24. Biol Blood Marrow Transplant. 2007. PMID: 17889358 - Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
Cho BS, Lee SE, Song HH, Lee JH, Yahng SA, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Cho BS, et al. Biol Blood Marrow Transplant. 2012 Jul;18(7):1136-43. doi: 10.1016/j.bbmt.2012.01.010. Epub 2012 Jan 16. Biol Blood Marrow Transplant. 2012. PMID: 22261380 - Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A. Pavletic SZ, et al. Am J Hematol. 2005 Apr;78(4):265-74. doi: 10.1002/ajh.20275. Am J Hematol. 2005. PMID: 15795914 - Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H. Wolff D, et al. Biol Blood Marrow Transplant. 2010 Dec;16(12):1611-28. doi: 10.1016/j.bbmt.2010.06.015. Epub 2010 Jun 25. Biol Blood Marrow Transplant. 2010. PMID: 20601036 - Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, Nepp J, Lawitschka A, Heiligenhaus A, Seitz B, Messmer EM, Meyer-ter-Vehn T, Basara N, Greinix H, Datiles MB, Lee SJ, Pavletic SZ, Wolff D. Dietrich-Ntoukas T, et al. Cornea. 2012 Mar;31(3):299-310. doi: 10.1097/ICO.0b013e318226bf97. Cornea. 2012. PMID: 22157574
Cited by
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.
Zhang E, Phan P, Zhao Z. Zhang E, et al. Acta Pharm Sin B. 2023 May;13(5):1789-1827. doi: 10.1016/j.apsb.2022.08.020. Epub 2022 Aug 28. Acta Pharm Sin B. 2023. PMID: 37250173 Free PMC article. Review. - Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
Novitzky-Basso I, Schain F, Batyrbekova N, Webb T, Remberger M, Keating A, Mattsson J. Novitzky-Basso I, et al. PLoS One. 2023 Mar 9;18(3):e0282753. doi: 10.1371/journal.pone.0282753. eCollection 2023. PLoS One. 2023. PMID: 36893113 Free PMC article. - Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease.
Mansourian A, Bahar B, Moosavi MS, Amanlou M, Babaeifard S. Mansourian A, et al. J Dent (Tehran). 2017 Nov;14(6):313-320. J Dent (Tehran). 2017. PMID: 29942325 Free PMC article. - Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia.
Ji SM, Bao XB, Lu J, Ma X, Tao T, Sun AN, Wu DP, Xue SL. Ji SM, et al. Indian J Hematol Blood Transfus. 2017 Dec;33(4):525-533. doi: 10.1007/s12288-017-0783-2. Epub 2017 Feb 8. Indian J Hematol Blood Transfus. 2017. PMID: 29075063 Free PMC article. - Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation.
Petruskevicius I, Ludvigsen M, Hjortebjerg R, Sørensen BS, Kamper P, Vase M, Oestgaard LG, Nielsen B, Honoré B, Bjerre M, Rabinovich GA, d'Amore FA. Petruskevicius I, et al. Bone Marrow Transplant. 2016 Oct;51(10):1387-1390. doi: 10.1038/bmt.2016.127. Epub 2016 May 23. Bone Marrow Transplant. 2016. PMID: 27214079 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources